Novo Nordisk: Wegovy Pill Sales Strong, But Is NVO a Buy?

Nov 12, 2026

Bobby Quant Team

💡 Key Takeaway

Novo Nordisk's successful Wegovy pill launch supports its high-volume/low-price strategy, and with the stock down 70% and a 4.4% dividend yield, the risk/reward looks favorable for value and income investors.

What Happened: JPMorgan's Prediction Comes True

JPMorgan analyst Richard Vosser predicted strong sales for Novo Nordisk's new Wegovy pill ahead of the company's earnings report. That prediction proved accurate: Novo Nordisk has now recorded more than 8 million cumulative prescriptions for the pill since its launch, making it even more successful than the Wegovy shot.

Novo Nordisk was already first to market with a GLP-1 weight-loss shot, creating an entirely new drug category. The company then became first to market with a GLP-1 pill, which is important because many patients prefer pills over injections. The strong adoption of the pill suggests that Novo Nordisk's strategy is resonating with patients and doctors.

However, the company's operating profit fell 9% year over year in the quarter. Management had signaled this decline, as Novo Nordisk is intentionally shifting to a high-volume, low-price model. The lower prices are currently depressing revenues and earnings, but the company believes this is a necessary step to capture a larger share of the massive obesity market.

While the Wegovy pill's strong sales are encouraging, the full success of the strategy won't be clear until profits start to recover. Additionally, competition is intensifying: Eli Lilly already has its own GLP-1 pill on the market, and other competitors are developing similar drugs.

What This Means for Me

If you hold NVO, the strong pill sales are a positive signal, but be prepared for continued volatility as the company transitions. Investors with exposure to the healthcare sector may want to consider NVO as a value play, but should also watch Eli Lilly (LLY) for competitive developments. Those seeking dividend income might find NVO attractive, but ensure it fits your risk tolerance given the stock's recent decline.

Why It Matters: Valuation and Future Growth

The strong sales of the Wegovy pill are a positive signal that Novo Nordisk's transition is on track. The pill could help the company reach more patients and drive long-term growth. But investors must weigh this against near-term financial pressure and increasing competition.

Novo Nordisk's stock has fallen about 70% from its 2024 peak, leaving it at a valuation that is historically low. The price-to-sales, price-to-earnings, and price-to-book ratios are all below their five-year averages. For value investors, this could represent an attractive entry point.

Income investors may also find the stock appealing: it offers a 4.4% dividend yield, well above the pharmaceutical industry average of around 1.3%. The dividend is supported by a conservative payout ratio of 33%, meaning it is likely sustainable.

Still, risks remain. The high-volume, low-price strategy is compressing margins, and Eli Lilly and other competitors are vying for market share. The success of the plan hinges on Novo Nordisk's ability to grow volume enough to offset lower prices. If it can, the stock could be a long-term winner; if not, the decline may continue.

Stock to Watch

Stocks	Impact	Analysis
LLY	Neutral	As a key competitor with its own GLP-1 pill, Lilly faces both opportunities and threats from Novo Nordisk's success. The overall market is large enough for multiple players, but competition could pressure pricing.
JPM	Neutral	JPMorgan's accurate prediction enhances its reputation for insightful healthcare research, but the direct financial impact on JPM is minimal.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.